卵巢癌的抗血管生成治疗：有待证实的巨大期望。 - Suppr

Suppr

超能文献

Anti-angiogenic therapy in ovarian cancer: a great expectation to be confirmed.

作者信息

González Martín Antonio

出版信息

Clin Transl Oncol. 2009 Sep;11(9):559-60. doi: 10.1007/s12094-009-0404-0.

DOI:10.1007/s12094-009-0404-0

PMID:19775993

Abstract

摘要

相似文献

Anti-angiogenic therapy in ovarian cancer: a great expectation to be confirmed.

Clin Transl Oncol. 2009 Sep;11(9):559-60. doi: 10.1007/s12094-009-0404-0.

New drugs for ovarian cancer.

Clin Adv Hematol Oncol. 2008 Feb;6(2):91-3.

Success of bevacizumab trials raises questions for future studies.

J Natl Cancer Inst. 2005 Jul 6;97(13):950-1. doi: 10.1093/jnci/dji194.

Bevacizumab in the treatment of ovarian cancer.

Expert Rev Anticancer Ther. 2007 Oct;7(10):1339-45. doi: 10.1586/14737140.7.10.1339.

Neoadjuvant bevacizumab in a granulosa cell tumor of the ovary: a case report.

Anticancer Res. 2010 Nov;30(11):4767-8.

Current status on biologic therapies in the treatment of epithelial ovarian cancer.

Curr Treat Options Oncol. 2009 Apr;10(1-2):54-66. doi: 10.1007/s11864-009-0100-x. Epub 2009 Apr 21.

Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer.

Nat Rev Drug Discov. 2004 May;3(5):391-400. doi: 10.1038/nrd1381.

Bevacizumab plus microtubule targeting agents in heavily pre-treated ovarian cancer patients: a retrospective study.

Bull Cancer. 2011 Oct;98(9):80-9. doi: 10.1684/bdc.2011.1436.

Combined anti-angiogenic therapy against VEGF and integrin alphaVbeta3 in an orthotopic model of ovarian cancer.

Cancer Biol Ther. 2009 Dec;8(23):2263-72. doi: 10.4161/cbt.8.23.10134. Epub 2009 Dec 19.

Experience with bevacizumab in the management of epithelial ovarian cancer.

J Clin Oncol. 2007 Jul 10;25(20):2902-8. doi: 10.1200/JCO.2007.12.1509.

引用本文的文献

Effect of Mad2 on paclitaxel-induced cell death in ovarian cancer cells.

J Huazhong Univ Sci Technolog Med Sci. 2010 Oct;30(5):620-5. doi: 10.1007/s11596-010-0553-y. Epub 2010 Nov 10.

Epithelial ovarian carcinoma: current evidences and future perspectives in the first-line setting.

Clin Transl Oncol. 2010 Jun;12(6):418-30. doi: 10.1007/s12094-010-0529-1.

本文引用的文献

Current status of anti-angiogenic agents in the treatment of ovarian carcinoma.

Clin Transl Oncol. 2009 Sep;11(9):589-95. doi: 10.1007/s12094-009-0409-8.

Angiogenesis and ovarian cancer.

Clin Transl Oncol. 2009 Sep;11(9):564-71. doi: 10.1007/s12094-009-0406-y.

Cancer statistics, 2009.

CA Cancer J Clin. 2009 Jul-Aug;59(4):225-49. doi: 10.3322/caac.20006. Epub 2009 May 27.

Evaluation of new platinum-based treatment regimens in advanced-stage ovarian cancer: a Phase III Trial of the Gynecologic Cancer Intergroup.

J Clin Oncol. 2009 Mar 20;27(9):1419-25. doi: 10.1200/JCO.2008.19.1684. Epub 2009 Feb 17.

Phase II study of bevacizumab in patients with platinum-resistant ovarian cancer or peritoneal serous cancer.

J Clin Oncol. 2007 Nov 20;25(33):5180-6. doi: 10.1200/JCO.2007.12.0782.

Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: a Gynecologic Oncology Group Study.

J Clin Oncol. 2007 Nov 20;25(33):5165-71. doi: 10.1200/JCO.2007.11.5345.

Avoiding bevacizumab related gastrointestinal toxicity for recurrent ovarian cancer by careful patient screening.

Gynecol Oncol. 2007 Oct;107(1):118-23. doi: 10.1016/j.ygyno.2007.06.004. Epub 2007 Jul 23.

Intraperitoneal chemotherapy for optimally debulked advanced ovarian cancer: a new standard in patient care?

Clin Transl Oncol. 2007 Jul;9(7):409-11. doi: 10.1007/s12094-007-0077-5.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验